Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial

耐受性 安慰剂 医学 人口 锥体外系症状 精神分裂症(面向对象编程) 临床终点 随机对照试验 不利影响 内科学 精神科 抗精神病药 病理 环境卫生 替代医学
作者
John H. Krystal,John M. Kane,Christoph U. Correll,David Walling,Matthew Leoni,Sridhar Duvvuri,Shrinal Patel,Ih Chang,Philip Iredale,Lillian Frohlich,Stacey Versavel,Pamela Perry,Raymond Sanchez,John J. Renger
出处
期刊:The Lancet [Elsevier]
卷期号:400 (10369): 2210-2220 被引量:38
标识
DOI:10.1016/s0140-6736(22)01990-0
摘要

Emraclidine is a novel, brain-penetrant, highly selective M4 receptor positive allosteric modulator in development for the treatment of schizophrenia. We aimed to evaluate the safety and tolerability of multiple ascending doses of emraclidine in patients with schizophrenia.We conducted a two-part, randomised, phase 1b trial in the USA. Eligible participants were aged 18-50 years (part A) or 18-55 years (part B) with a primary diagnosis of schizophrenia per the Diagnostic and Statistical Manual of Mental Disorders 5th edition, as confirmed by the Mini International Neuropsychiatric Interview, and extrapyramidal symptom assessments indicating normal to mild symptoms at screening. Part A evaluated the safety and tolerability of emraclidine in five cohorts of participants with stable schizophrenia who received ascending oral doses of emraclidine 5-40 mg (40 mg was administered as 20 mg twice daily) or placebo at a single US site. Part B was a double-blind, randomised, placebo-controlled study that enrolled adults with acute schizophrenia across five US sites; participants were randomly assigned (1:1:1) to receive emraclidine 30 mg once daily, emraclidine 20 mg twice daily, or placebo for 6 weeks (doses established in part A). The primary endpoint was safety and tolerability, assessed in the safety population (participants who received at least one dose of emraclidine or placebo). This trial is now complete and is registered with ClinicalTrials.gov, NCT04136873.Between Sept 23, 2019, and Sept 17, 2020, 118 patients were assessed for eligibility and 49 were randomly assigned across five cohorts in part A. 44 participants completed the study, with 36 participants receiving emraclidine and eight receiving placebo. The two highest doses tested were selected for part B. Between Oct 12, 2020, and May 7, 2021, 148 patients were assessed for eligibility and 81 were randomly assigned to emraclidine 30 mg once daily (n=27), emraclidine 20 mg twice daily (n=27), or placebo (n=27) in part B. Incidence of adverse events (14 [52%] of 27 participants in the emraclidine 30 mg once daily group, 15 [56%] of 27 in the emraclidine 20 mg twice daily group, and 14 [52%] of 27 in the placebo group), clinical assessments, and weight changes were similar across groups. The most common adverse event was headache (15 [28%] of 54 participants in the emraclidine groups, seven [26%] of 27 in the placebo group). Modest, transient increases in blood pressure and heart rate in emraclidine groups observed at treatment initiation diminished over time and were not considered clinically meaningful by week 6.These data support further investigation of emraclidine as a once-daily treatment for schizophrenia without need for titration and with a potentially favourable side-effect profile.Cerevel Therapeutics.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
SOLOMON应助我来回收数据采纳,获得10
1秒前
小尹同学应助朴老弟采纳,获得30
1秒前
1秒前
乐乐应助黑色幽默采纳,获得10
2秒前
若水应助sy采纳,获得20
2秒前
2秒前
2秒前
李健应助baiqi采纳,获得10
3秒前
3秒前
4秒前
LGY完成签到 ,获得积分10
4秒前
李健的小迷弟应助常瑾瑜采纳,获得10
4秒前
NUS发布了新的文献求助10
4秒前
沐沐发布了新的文献求助10
4秒前
wtbxsjy完成签到,获得积分10
5秒前
5秒前
chi发布了新的文献求助10
5秒前
单于访枫发布了新的文献求助10
6秒前
罗布林卡发布了新的文献求助10
6秒前
领导范儿应助辛勤的乌采纳,获得10
7秒前
7秒前
饿饿饿了发布了新的文献求助30
8秒前
李健应助小陈爱困采纳,获得10
8秒前
btsforever完成签到 ,获得积分10
8秒前
ggg完成签到,获得积分10
8秒前
追寻的丹烟完成签到,获得积分10
9秒前
撒大大发布了新的文献求助10
9秒前
略略略完成签到,获得积分10
9秒前
11秒前
古古哒完成签到,获得积分10
11秒前
123发布了新的文献求助10
11秒前
12秒前
隐形曼青应助刘喵喵采纳,获得10
14秒前
14秒前
15秒前
15秒前
16秒前
英俊的铭应助撒大大采纳,获得10
16秒前
乔巴发布了新的文献求助10
16秒前
柠檬精完成签到 ,获得积分10
17秒前
高分求助中
The three stars each: the Astrolabes and related texts 1100
Sport in der Antike 800
De arte gymnastica. The art of gymnastics 600
Berns Ziesemer - Maos deutscher Topagent: Wie China die Bundesrepublik eroberte 500
Stephen R. Mackinnon - Chen Hansheng: China’s Last Romantic Revolutionary (2023) 500
Sport in der Antike Hardcover – March 1, 2015 500
Psychological Warfare Operations at Lower Echelons in the Eighth Army, July 1952 – July 1953 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2428077
求助须知:如何正确求助?哪些是违规求助? 2113814
关于积分的说明 5358004
捐赠科研通 1841800
什么是DOI,文献DOI怎么找? 916570
版权声明 561464
科研通“疑难数据库(出版商)”最低求助积分说明 490219